74 related articles for article (PubMed ID: 38458638)
1. NK cell-based therapeutics for lung cancer.
Pockley AG; Vaupel P; Multhoff G
Expert Opin Biol Ther; 2020 Jan; 20(1):23-33. PubMed ID: 31714156
[No Abstract] [Full Text] [Related]
2. B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?
Malapelle U; Parente P; Pepe F; Di Micco MC; Russo A; Clemente C; Graziano P; Rossi A
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555714
[TBL] [Abstract][Full Text] [Related]
3. Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells.
Parodi M; Centonze G; Murianni F; Orecchia P; Andriani F; Roato I; Gardelli C; Balsamo M; Moro M; Taiè G; Pastorino U; Petretto A; Lavarello C; Milione M; Sozzi G; Roz L; Vitale M; Bertolini G
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458638
[TBL] [Abstract][Full Text] [Related]
4. Conversion to stem-cell state in response to microenvironmental cues is regulated by balance between epithelial and mesenchymal features in lung cancer cells.
Andriani F; Bertolini G; Facchinetti F; Baldoli E; Moro M; Casalini P; Caserini R; Milione M; Leone G; Pelosi G; Pastorino U; Sozzi G; Roz L
Mol Oncol; 2016 Feb; 10(2):253-71. PubMed ID: 26514616
[TBL] [Abstract][Full Text] [Related]
5. Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAM- Lung Cancer-Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis.
Bertolini G; D'Amico L; Moro M; Landoni E; Perego P; Miceli R; Gatti L; Andriani F; Wong D; Caserini R; Tortoreto M; Milione M; Ferracini R; Mariani L; Pastorino U; Roato I; Sozzi G; Roz L
Cancer Res; 2015 Sep; 75(17):3636-49. PubMed ID: 26141860
[TBL] [Abstract][Full Text] [Related]
6. CXCR4 is involved in CD133-induced EMT in non-small cell lung cancer.
Tu Z; Xie S; Xiong M; Liu Y; Yang X; Tembo KM; Huang J; Hu W; Huang X; Pan S; Liu P; Altaf E; Kang G; Xiong J; Zhang Q
Int J Oncol; 2017 Feb; 50(2):505-514. PubMed ID: 28000861
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p.
Lu W; Zhang H; Niu Y; Wu Y; Sun W; Li H; Kong J; Ding K; Shen HM; Wu H; Xia D; Wu Y
Mol Cancer; 2017 Jul; 16(1):118. PubMed ID: 28697764
[TBL] [Abstract][Full Text] [Related]
8. IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer.
Kachroo P; Lee MH; Zhang L; Baratelli F; Lee G; Srivastava MK; Wang G; Walser TC; Krysan K; Sharma S; Dubinett SM; Lee JM
J Exp Clin Cancer Res; 2013 Nov; 32(1):97. PubMed ID: 24274066
[TBL] [Abstract][Full Text] [Related]
9. B7-H3 in Pediatric Tumors: Far beyond Neuroblastoma.
Bottino C; Vitale C; Dondero A; Castriconi R
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444389
[TBL] [Abstract][Full Text] [Related]
10. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy.
Wolf NK; Kissiov DU; Raulet DH
Nat Rev Immunol; 2023 Feb; 23(2):90-105. PubMed ID: 35637393
[TBL] [Abstract][Full Text] [Related]
11. Resistance to natural killer cell immunosurveillance confers a selective advantage to polyclonal metastasis.
Lo HC; Xu Z; Kim IS; Pingel B; Aguirre S; Kodali S; Liu J; Zhang W; Muscarella AM; Hein SM; Krupnick AS; Neilson JR; Paust S; Rosen JM; Wang H; Zhang XH
Nat Cancer; 2020 Jul; 1(7):709-722. PubMed ID: 35122036
[TBL] [Abstract][Full Text] [Related]
12. Functional visualization of NK cell-mediated killing of metastatic single tumor cells.
Ichise H; Tsukamoto S; Hirashima T; Konishi Y; Oki C; Tsukiji S; Iwano S; Miyawaki A; Sumiyama K; Terai K; Matsuda M
Elife; 2022 Feb; 11():. PubMed ID: 35113018
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive Traits of the Hybrid Epithelial/Mesenchymal Phenotype.
Sahoo S; Nayak SP; Hari K; Purkait P; Mandal S; Kishore A; Levine H; Jolly MK
Front Immunol; 2021; 12():797261. PubMed ID: 34975907
[TBL] [Abstract][Full Text] [Related]
14. Distinct contributions of partial and full EMT to breast cancer malignancy.
Lüönd F; Sugiyama N; Bill R; Bornes L; Hager C; Tang F; Santacroce N; Beisel C; Ivanek R; Bürglin T; Tiede S; van Rheenen J; Christofori G
Dev Cell; 2021 Dec; 56(23):3203-3221.e11. PubMed ID: 34847378
[TBL] [Abstract][Full Text] [Related]
15. Blocking HIF to Enhance NK Cells: Hints for New Anti-Tumor Therapeutic Strategies?
Vitale M; Parodi M
Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696251
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
